3030 Callan Road
9 articles with Ansun Biopharma
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection
Ansun Biopharma, Inc., announced that the first patient has been enrolled in its Phase 3 clinical trial evaluating the efficacy and safety of DAS181 for the treatment of hospitalized, immunocompromised patients with lower respiratory tract parainfluenza virus infection.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Ansun Biopharma, Inc., today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
Ansun Biopharma is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral infections,
Ansun is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.
Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181.
Ansun BioPharma Announces Two Publications Showing Inhibitory Effects Of DAS181 On Respiratory Syncytial Virus (RSV) And Human Metapneumovirus (hMPV)